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PATRÍCIA CAMPOS JUCÁ – ACBC-RJ1; LAERCIO LOURENÇO – TCBC-SP2; RUBENS KESLEY – TCBC-RJ1;
EDUARDO LINHARES RIELLO DE MELLO – TCBC-RJ1; IVANIR MARTINS DE OLIVEIRA 3; JOSÉ HUMBERTO SIMÕES CORREA – TCBC-RJ1
A B S T R A C T
Objective: To compare the survival and prognosis after surgical treatment of patients with gastric adenocarcinoma which extends
to the muscular layer (T2), and patients whose tumor invades the subserosa (T3). Methods: This was a retrospective study of 122
patients with gastric cancer invading the muscularis propria and subserosa, undergoing surgical treatment from January 1997 to
December 2008 and followed-up until December 2010. We analyzed demographic, surgical and pathological variables. Results: Of
the 122 patients, 22 (18%) were excluded from the final analysis because they showed: positive margin or less than 15 lymph nodes
in the surgical specimen, early postoperative mortality and second primary tumors. Among the 100 patients included, 75 had tumors
inveding the muscularis propria (T2) and 25 with extension to the subserosa (T3). Overall survival was 83.8%, and 90.6% for T2 and
52.1% or T3. Univariate analysis showed statistical significance in: lymph node metastasis (p = 0.02), tumor size (p = 0.000), tumor
pathological stage (p = 0.000), lymph node pathologic stage (p = 0.000) and staging by classification of groups TNM-UICC/AJCC, 2010
(p = 0.000). In multivariate analysis, independent prognostic factors were tumor size and lymph node pathological staging (pN).
Conclusion: The lymph node status and tumor size are independent prognostic factors in tumors with invasion of the muscularis
propria and in tumors with invasion of subserosa. T2 lesions have smaller size, lower rate of lymph node metastasis and therefore
better prognosis than T3.
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INTRODUCTION
The incidence of gastric cancer (GC) is decreasingworldwide since 1950. However, its aggressiveness,
malignancy and, consequently, its prognosis remains
unchanged, representing the second leading cause of cancer
death, with 628,000 (12.1%) deaths per year1. In Brazil,
according to the National Cancer Institute2 (INCA), the
estimated incidence of GC for the year 2011 pointed to
21,500 new cases of the disease, 13,820 being in men
(64.3%) and 7,680 in women (35, 7%), corresponding to
an estimated risk of 14 new cases per 100,000 men and
eight for every 100,000 women, consolidating its position
as the fifth malignant tumor in incidence, the second of
the gastrointestinal tract.
Gastric adenocarcinoma (GA) is the most
common histological type (95%), originating in the
epithelium of the gastric mucosa and progressively
involving the entire stomach wall to reach the serosa and
adjacent structures. Surgical treatment remains the only
curative treatment modality3,4 and the extent of resection
depends on pre and intraoperative localization of the tu-
mor, the degree of penetration of the tumor in the stomach
wall, invasion of adjacent organs and lymph node
metastasis5 ,6.
The identification of prognostic factors in GA
is important to establish the staging and determining
therapeutic strategies. The tumor that invades the mucosa
and submucosa layers (T1), independent of lymph node
status, is classified as early gastric cancer (EGC), with
five-year survival of 93.5% of operated patients, 72.8%
being in those with positive nodes and 95.6% for those
with no lymph node metastases. When the tumor goes
beyond the submucosal layer and invades the muscularis
propria (T2), it is classified as advanced gastric cancer
(AGC), but it is considered an intermediate stage of tu-
mor progression between the AGC and EGC, with better
prognosis and survival in five years7-14. This category (T2),
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infrequent, represents 8% to 18% of resected GCs in
Japan13.
The TNM classification of the 2010 American
Joint Committee on Cancer (AJCC) establishes criteria for
staging based on tumor invasion of the gastric wall, lymph
node invasion and distant metastases. Tumors are grouped
into categories according to the stomach wall invasion
(T), number of positive lymph nodes (N) and presence of
distant metastases (M). In 1998, the College of American
Pathologists recommended the subclassification of T2 into
T2a “ invasion of the muscularis propria, and T2b “
invasion of the subserosa, to allow for better prognostic
and survival evaluation in these patients15. In the beginning
of this study, we used the sixth edition of the classification
TNM-UICC/AJCC16, which defined this subdivision,
recommended by the College of American Pathologists
for T2, however, with no change in the staging of the
groups that include T2 lesions (stages IB, II and IIIA), ie
pT2aN0 and pT2bN0 stage I and pT2aN1 and pT2bN1
stage II. Only lymph node commitment determined the
change of stage16.
In  2010 the seventh ed i t ion of  the
classification TNM-UICC/AJCC17 was published, which
separated tumors restricted to the muscularis propria
and those invading the subserosa, T2 and T3,
respectively, into different categories and stages. The
T2a remains in the T2 category and T2b passes to
category T3. The nodal pathologic stage (pN) was also
modified, N1 comprising one to two lymph nodes, N2
three to six, N3a seven to 15 and N3b 16 or more
lymph nodes. In staging by groups, categories T2 and
T3 were separated, T2N0 becoming stage IB, T3N0
and T2N1 stage IIA, T3N1 and T2N2 stage IIB, T3N2
and T2N3 stage IIIA and T3N3 stage IIIB. This current
classification excludes tumors of the esophagogastric
junction (EGJ) or that originate in the stomach less
than 5cm to the EGJ and invade it. These tumors, of
poor prognosis, are now staged as esophageal
adenocarcinomas17. This separation of T2 and T3 in
different groups of patients confirms that T2 GC has a
different prognosis from T3. The identification of
prognostic factors related to T2 is important because,
in this intermediate stage, the cancer may be curable
with an appropriate surgical procedure that includes
D2 lymphadenectomy.
There are few published studies evaluating
the prognostic factors in patients with T28,10,13,14.
Several studies suggest a favorable prognosis for
survival with T2 in five years, close to T18,18-21. Other
series report that the subclassification of T2 (T2/T3)
has no value in the presence of metastatic lymph
nodes, since these latter are the determinants of
prognosis10,22.
This study aims to compare survival and prognosis
of patients with T2 and T3 gastric adenocarcinoma after
surgical treatment.
METHODS
We studied 122 patients with GA, with
invasion of the muscularis propria (T2) and invasion of
subserosa (T3). All patients were treated at the
Department of Abdominopelvic Surgery, Cancer Hos-
pital I, INCA, between January 1997 and December
2008, and followed up until December 2010. The study
was approved by the Ethics in Research Committee of
the National Cancer Institute, registration number 69/
2009, and of the Federal University of São Paulo under
the record 1484/2009.
Of the 122 patients, 22 were excluded from the
final analysis: one due to margins compromised by neoplasia
in the final histopathology (0.8%); four died in the first 30
postoperative days (3.2%); four had a second primary tu-
mor (3.2%); and 13 had fewer than 15 resected lymph
nodes (10.6%).
Of the 100 patients included, 75 had tumors with
invasion of the muscularis propria (T2), and 25, with invasion
of subserosa (T3), according to the seventh edition of the
classification TNM-UICC/AJCC, 201017. The radical surgical
treatment followed the criteria of the Japanese Gastric
Cancer   Association (JGCA)5 according to tumor site. A
subtotal gastrectomy (STG) was performed in tumors of
the distal stomach, and a total gastrectomy (TG) in tumors
of the proximal third. Tumors in the middle third underwent
STG or GT depending on the distance from the proximal
edge of the tumor to the GEJ.
Lymphadenectomy was performed based on the
location of the tumor in the stomach, including the lymph
nodes of level I and / or II, according to the report of the
surgeon and the criteria of the Japanese classification5,
being considered adequate the sampling of at least 15
resected lymph nodes. The resection was considered curative
(R0) in the absence of macroscopic or microscopic residual
tumor, with margins, proximal and distal, free of neoplasia
at pathology exam during surgery, and in the absence of
distant disease6.
The demographic variables studied were age and
gender. Patients were divided into two age groups, with
60 years or less and more than 60 years, determined by
the median and average age.
Variables included the type of surgical
gastrectomy, total or subtotal, and the extent of
lymphadenectomy performed, level 1 (D1) and level 1 and
2 (D2), described by the surgeon.
The macroscopic pathologic variables analyzed
according to the mean and median found were tumor size
(d” 5 cm or> 5 cm) and the number of lymph nodes resected
(d” 33 lymph nodes and> 33 lymph nodes). The macroscopic
appearance of tumors was analyzed according to the
classification of Borrmann23 for AGC, including the zero
category according to the Japanese classification for EGC
(JGCA)5, when the macroscopic appearance of tumors
suggested early disease. The location in the stomach
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(proximal, medium and distal third) was based on the JGCA
Japanese classification5.
The microscopic pathologic variables included
extension of tumor invasion in the gastric wall, whether
the muscularis propria or the subserosa, the degree of
cellular differentiation according to the classification of
Broders24, moderately and well differentiated vs. poorly
differentiated, and the presence or absence of venous,
lymphatic and neural invasion and the presence or absence
of lymph node compromised, the number of lymph nodes
involved by neoplasia and grouping by stages, according
to the seventh edition of the TNM-UICC/AJCC
classification17.
Statistical Analysis
The data obtained were analyzed using: 1)
descriptive analysis, by the distribution of frequencies and
simple percentages, medians, averages, standard
deviations (SD) and confidence intervals (CI); 2) Fisher’s
exact test, two-tailed mode; 3) Kaplan-Meier method
for survival analysis, applying the Log Rank test to com-
pare survival curves. Non-cancer deaths were not
censored; 4) Cox Proportional Hazards method for
multivariate analysis of prognostic factors, Harzard ratio
by Z test; and 5) the significance level of 5% probability.
The variables without significance were marked with the
initials NS.
RESULTS
The estimated overall survival at five years was
81.8%, with a mean follow-up of 124 ± 6.3 months (95%
CI, 111-136 months), and can be seen in figure 1.
The mean and median age was 60 years (25 to
78 years in T2 and 42 to 83 years in T3). Regarding gender,
there was equivalence: 53% were male and 47% female.
In males the fifth decade of life predominated. Age (p =
0.78) and sex (p = 0.48) did not influence the prognosis of
patients.
STG was performed in 74% (59% in T2 and 15%
in T3) and GT in 26% (16% in T2 and 10% in T3).
Seventeen patients underwent D1 lymphadenectomy, and
in all more than 15 lymph nodes were found in the surgical
specimen. As for prognosis, the variables type of operation
and extent of lymphadenectomy did not interfere
significantly in five-year survival.
The macroscopic pathologic variables studied
were location, macroscopic aspect, tumor size and number
of lymph nodes resected. There was significant difference
in the prognosis of patients classified as T2 and T3 only in
relation to tumor size d” 5 cm and> 5 cm (p = 0.00).
Tumors were located in the distal third of the
stomach in 57% of patients, in the middle third in 31%
and in the proximal third on 12%. The average number of
lymph nodes resected was 33, ranging from 15 to 75 lymph
nodes. The mean and median tumor size was 5 cm. Patients
with tumors d” 5cm showed five-year survival of 94.6%,
and > 5cm, 69% (p = 0.000) (Figure 2). When comparing
tumor size and pathologic stage (pT), there were also no
significant differences. In pT2 d” 5cm (59%) and> 5cm
(41%), survival was 96.5% and 82.1%, respectively (p
<0.005). In pT3 d” 5cm (32%) and> 5cm (68%), survival
was 80% and 45%, respectively (p <0.005).
As for tumor penetration in the gastric wall (pT),
five-year survival was significantly greater in pT2 (90.6%)
than in T3 (52.1%) (p = 0.000) (Figure 3 ).
Lymph node metastases occurred in 52% of
patients with five-year surviving of 72.4%, which, when
compared to the survival of 90.3% of node-negative
patients, was statistically significant (p <0.02). The lymph
node pathologic stage – pN “ also demonstrated
significant differences in patient survival (p = 0.000) (Fi-
gure 4). When analyzing pT2 and pT3 tumors, pN also
had a significant impact on survival (p <0.001) (Table
1), which also occurred in the staging by TNM-UICC/
AJCC 17 groups (p = 0.000).
Figure 2 - Five-year survival curve pursuant to size,
demonstrating a significant difference in the prognosis
of tumors d” 5cm and> 5cm. (P = 0.000). Kaplan-
Meier method.
Figure 1 - Five-year survival curve of the 100 patients with T2
and T3 GA. Kaplan-Meier method.
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The degree of tumor cell differentiation and the
presence or absence of venous, lymphatic and nerve
infiltration were not significant.
Of the 100 patients studied, 16% had disease
recurrence during follow-up, two of whom are still alive,
with evidence of disease, one with bone metastases
and other metastatic lymph nodes in the hepatic pedicle.
Recurrence rate was significantly higher in T3. Of the
75 patients with T2, eight (10.7%) relapsed, six at
distance (liver and bone), one in lymph nodes and one
in the peritoneum. Eight (32%) patients with T3 had
recurrences, five at distance (liver, bones and lungs),
one in lymph nodes and two in the peritoneum (p
<0.0171). There were 17 (17%) deaths, 14 due to the
GC and three from causes unrelated to the tumors. All
patients were followed for an average period of 124
months, a minimum of four and a maximum of 152
months.
In univariate analysis (Table 2), prognostic factors
associated with survival were tumor size (p = 0.000), tu-
mor invasion in the gastric wall “ pT (p = 0.000), presence
of lymph node metastasis (p = 0.02), number of positive
lymph nodes – pN “ (p = 0.000) and group staging by the
TNM-UICC/AJCC17 classification (p = 0.000). Multivariate
analysis showed that independent prognostic factors were
tumor size (p <0.001) and lymph node involvement (p
<0.016) .
DISCUSSION
There are many studies on AGC, but few evaluate
the prognostic factors of patients with T2, most of them
with a similar sample of this study and controversial results.
The greatest sample was the Korean study of Park et al.19,
with 442 patients. It is also unclear which of these prognostic
factors are relevant in T210. The possible better outcome of
T2 raises criticisms towards its classification as AGC. The
T2 is considered of intermediate prognosis, between EGC
and AGC7-14.
The identification of prognostic factors related
to GC is crucial for prognostic evaluation and decision
of the best treatment strategy, surgical and adjuvant.
We found studies that also used the greatest diameter
of the tumor to assess its size, with medians of 3.5,
3.619 and 4.2cm21. Several studies19,20,22,25 have found
significant differences related to tumor size in the
univariate analysis. Fotia et al.10 analyzed tumors d”
2 cm, 2 to 4 cm, and> 4cm and found no significant
difference in survival at five years. In the present study,
tumor size was an independent prognostic factor,
Table 1- . Analysis of pathologic lymph node staging in T2 and T3.
p N n pT2 (%) S % CI 95% n pT3 (%) S % IC 95%
pN0 44 58.7 92 126-151 4 16 66.7 29-76
pN1 9 12 alive - 5 20 live -
pN2 11 14.7 89 79-111 7 28 62.5 42-85
pN3a 8 10.7 75 36-68 9 38 38.1 18-50
pN3b 3 4.0 alive - 0 - - -
Tota l 7 5 1 0 0 - - 2 5 1 0 0 - -
Legend: n (number of cases); CI (confidence interval); S (survival estimate).
Figure 4 - Five-year survival curve pursuant to lymph node
pathological staging, demonstrating a significant
difference in the patients’ prognosis related to pN. (P
= 0.000). Kaplan-Meier.
Figure 3 - Five-year survival curve pursuant to pathological
staging of the tumor, demonstrating a significant
difference in the patients’ prognosis related to pT (p
= 0.000). Kaplan-Meier method.
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Table 2 - Univariate Analysis of survival according to the clinical features of the 100 patients with T2 and T3 gastric
adenocarcinoma.
Var iables Cases Deaths Al ive Months S D CI (95%) S
n % % p <
Total 100 17 83 83 124 6.3 111- 136 81.8 -
Age:
< 60 years 51 8 43 84.3 125 8.7 108- 142 82.1 0.780
> 60 years 49 9 40 81.7 113 7.5 93- 128 81.0
Gender:
Female 53 10 43 81.1 112 7.8 96- 127 80.0 0.480
Male 47 7 40 85.1 126 9.2 108- 144 84.0
Surgery:
STG 74 13 61 82.4 113 6.3 101- 126 81.2 0.920
TG 26 4 22 84.6 130 10.1 110- 150 83.8
Borrmann:
0 29 3 26 89.6 126 7.0 112- 140 88.4 0.290
I 5 2 3 60 67 20.8 26- 108 -
II 22 5 17 77.2 95 9.03 77- 112 80.0
III 37 6 31 83.7 117 13.3 91- 143 81.2
IV 7 1 6 85.7 74 9.1 56- 92 -
Size:
< 5 cm 52 2 50 96.1 146 4.1 138- 154 94.6 0.000
> 5 cm 48 15 33 68.7 96 8.8 79- 114 69.0
Location (third):
Proximal 12 1 11 91.6 140 11.8 116- 163 91.6 0.720
Medium 31 5 26 83.8 112 11.2 90- 134 84.2
Distal 57 11 46 80.7 111 6.7 98- 124 78.8
Thickness:
< 0.9 cm 55 6 49 89 133 7.8 117- 148 89.2 0.070
> 0.9 cm 45 11 34 75.5 103 8.4 86- 119 72.4
No lymph nodes:
< 33 59 10 49 83 125 7.6 110- 140 80.3 0.920
> 33 41 7 34 82.9 92 5.2 82- 103 83.6
Level difference:
G1/G2 34 7 27 79.4 97 6.9 83–111 79.9 0.700
G3 66 10 56 84.8 125 8.2 109–141 82.9
pT invasion:
T2 75 8 67 89.3 134 6.1 121–146 90.6 0.000
T3 25 9 16 64 63 7.7 48– 79 52.1
Venous invasion:
Yes 19 4 15 78.9 75 8.0 60– 91 73.3 0.360
No 81 13 68 83.9 126 6.6 113–139 83.4
Lymphatic invasion:
Yes 63 13 50 79.3 106 7.3 91–120 78.1 0.180
No 37 4 33 89.1 136 7.4 122–151 87.4
Perineural invasion
Yes 45 10 35 77.7 117 9.5 98–136 78.9 0.330
No 55 7 48 87.2 121 6.1 109–133 84.0
pN:
0 48 5 43 89.5 136 6.6 123–149 90.3 0.000
1 14 0 14 100 – – – –
2 18 4 14 77.7 87 8.3 71–104 77.6
3rd 17 8 9 52.9 41 6.1 29– 53 26.3
3b 5 0 5 100 – – – –
Stage:
Ib 44 4 40 90.9 139 6.3 129–151 92.0 0.000
Iia 13 1 12 92.3 109 8.2 93–125 90.9
Iib 16 2 14 87.5 97 6.1 85–109 91.6
IIIa 18 4 14 77.7 67 6.7 54– 80 73.4
IIIb 9 6 3 33.3 34 8.1 18– 50 0
Note: the Log-Rank Test; Degrees of freedom (GL).Legend: M (medium); SD (standard deviation); CI (confidence interval); S (estimated five-year
survival).
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58.7% of T2 being d” 5 cm and 68% of T3 being >
5cm.
The GA invading the muscularis propria has a
better prognosis than the tumor invading the
subserosa7,9,11,12,14,19,20,22,25,26, being an independent
prognostic factor in several studies14,19,20 26. In this study
T2 survival was significantly better than that of T3,
90.6% and 52%, respectively. When pT was analyzed
with other prognostic variables, such as the presence
of lymph node metastasis, tumor invasion in gastric wall
was not an independent prognostic factor. Sarela et
al.22 also found a significant difference in survival
between T2 and T3 (64% vs. 46%, p = 0.005); however,
when lymph node staging was adequate, with more
than 15 nodes resected, the authors found different
results: survival in patients N0 was similar for T2 and
T3 (90% vs. 86%, p = 0.8) and in patients with N1,
survival was not significantly different from T2 and T3
(56% vs. by 44%, p = 0.3). Fotia et al.10, in a study
including patients with less than 15 lymph nodes
resected, also found no difference in survival between
T2 and T3 (74% vs. 67%, p = 0.2). Park et al..19,
however, found a difference between T2 and T3,
independent of lymph node involvement, in a study
including only patients with more than 15 resected lymph
nodes (85% vs. 56%, p <0.001). In the study of Nitti et
al..26, pT was an independent prognostic factor, and T2
showed a significantly better prognosis than T3, with
five-year survival of 73% and 31%, respectively.
In the present study, lymph node metastases
occurred in 52% of patients, with a significant difference
in survival, 90.3% and 72.4%, respectively, with positive
and negative lymph nodes (p <0.02). Lymph node
metastases were more frequent in T3 (84%). Only 16% of
patients had node-negative T3. At T2, 59% were node-
negative and 41% node-positive. Lymph node involvement
was also a prognostic factor in univariate analysis of several
studies8,10,12,19,25. In the study of Sarela et al.22, two thirds of
T3 were associated with lymph node metastasis, as opposed
to only half of T2 (p <0.001).
The stratification of patients according to
pathological lymph node involvement (pN) also showed a
significant difference (p = 0.000). The T3 had the greatest
number of metastatic lymph nodes, which was progressively
higher in N1 (20%), N2 (28%) and N3 (36%). T2 survival
was better than T3, according to pN. In T2N0 survival was
92.6%, and in T3N0, 66.67%. All T2N1 and T3N1 patients
were alive at the end of the study. In T2N2 and T3N2,
survival was 89% vs. 62.5%, and in T2N3a and T3N3a it
was 45% vs. 38%, respectively. T2N3b patients were alive
until the end of the study and there were no patients T3N3b.
The pN was an independent prognostic factor. In the study
of Sarela et al..22, pN3 and pN2 categories accounted for a
quarter of T3 and only 3% of T2. Survival in pN0, pN1,
pN2 and pN3 was 83%, 44%, 11% and 0%, respectively.
The pN was the only independent prognostic factor in that
study.
Analysis of the 2010 TNM-UICC/AJCC17 staging
also showed a significant difference in survival at five years,
according to the stage groups. Patients stages IB, IIA and
IIB, which correspond to T2N0-N2 and T3N0-N1, showed
similar survival of 92%, 90.9% and 91.6% respectively,
and in stages IIIA and IIIB (T2N3 and T3N1-N3) survival was
73.4% and 0%, respectively. Two studies evaluated the
2010 TNM-UICC/AJCC classification for GC. Ahn et al.28
found better categorization by groups in the seventh edition,
mainly related to T2 and T3, N1 and N2. Kim et al..29 also
found better separation by staging subgroups, with different
prognoses.
Tumors with invasion of the muscularis propria
have a better prognosis than tumors invading the subserosa,
and this is because the deeper the tumor invasion into the
wall of the organ, the higher the rate of metastatic lymph
nodes. Sasako et al.30 demonstrated that lymph node
involvement was present in 47% of tumors that invade the
muscularis propria and in 64% of tumors invading the
subserosa.
The stomach has a well-developed lymphatic
system and lymphatic spread is the most common. Gastric
tumors confined to the muscularis propria have a lower
rate of lymph node metastasis, reducing the risk of spread,
having a better prognosis than tumors invading the
subserosa.
Despite advances in oncology, GC is still a disease
with poor prognosis. Nevertheless, in recent years the
detection of the disease at early stages, the systematization
of radical surgical treatment and onset of adjuvant therapy
has increased patients’ survival. It is possible that with
increased use of endoscopy, the improvement of public
health and socioeconomic development of the country, the
number of patients with GC restricted to the muscularis
propria (T2) becomes greater, effectively improving
prognosis and survival.
0In this study, lymph node status and tumor
greater than 5 cm in its greatest diameter were the factors
that determined the prognosis of patients with gastric cancer
that invades the muscularis propria and subserosa. The T2
GA were smaller and displayed lower number of metastatic
lymph nodes that T3, which determined the best prognosis
and five-year survival of patients with GA invasion of mus-
cular layer of the stomach when compared to those with
compromised subserosa.
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R E S U M O
Objetivo: Comparar a sobrevivência e os fatores prognósticos, após o tratamento cirúrgico de pacientes com adenocarcinoma
gástrico que compromete a camada muscular própria (T2), e de pacientes cujo tumor invade a subserosa (T3). Métodos: Estudo
retrospectivo de 122 pacientes com câncer gástrico invadindo a muscular própria e subserosa, submetidos ao tratamento cirúrgico
no período de janeiro de 1997 a dezembro de 2008 e acompanhados até dezembro de 2010. Foram analisadas variáveis demográficas,
cirúrgicas  e anatomopatológicas. Resultados: Dos 122 pacientes, 22 (18%) foram excluídos da análise final porque apresentaram:
margem positiva, mortalidade pós-operatória, segundo tumor primário e menos de 15 linfonodos na peça cirúrgica. Entre os 100
pacientes incluídos, 75 apresentavam tumores com invasão da muscular própria (T2) e 25 com invasão da subserosa (T3). A
sobrevivência global foi  83,8%, sendo 90,6% no T2 e 52,1% no T3. Na análise univariada apresentaram significância: metástase
linfonodal (p=0,02), tamanho do tumor (p=0,000), estadiamento patológico do tumor (p=0,000), estadiamento patológico linfonodal
(p=0,000) e estadiamento por grupos da classificação TNM-UICC/AJCC, 2010 (p=0,000) Na análise multivariada, os fatores prognós-
ticos independentes foram o tamanho do tumor e o estadiamento patológico linfonodal (pN). Conclusão: O comprometimento
linfonodal e o tamanho do tumor são fatores prognósticos independentes nos tumores com invasão da muscular própria e nos
tumores com invasão da subserosa. O T2 apresenta menor tamanho, menor taxa de linfonodos metastáticos e consequentemente,
melhor prognóstico que o T3.
Descritores: Prognóstico. Neoplasias. Neoplasias gástricas. Adenocarcinoma. Taxa de sobrevida.
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